Membranous Nephropathy Market Insights 2032 by Delveinsight | Argenx, Zai Lab Pty Ltd., Shanghai Jiaolian Drug Research and Development Co. Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, Acelyrin, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceutica

The market size of Membranous Nephropathy is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Gilead Sciences, Mallinckrodt, Mayo Clinic, Genentech Inc., GlaxoSmithKline, Roche Pharma AG, Apellis Pharmaceuticals Inc., and others…

[Nevada, United States] - DelveInsight's "Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Membranous Nephropathy, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Membranous Nephropathy Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Membranous Nephropathy Market Report:
The Membranous Nephropathy market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
In September, 2024: Shanghai Jiaolian Drug Research and Development Co., Ltd announced that the purpose of their study is to evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy
In August, 2024: BeiGene announced that the primary objective of their study is to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy who are on optimal supportive care.
In August, 2024: Hoffmann-La Roche announced that their study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).
In August, 2024: Hansa Biopharma AB announced that a Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.
In June, 2024: Apellis Pharmaceuticals, Inc. announced that a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
In a study by Storrar et al. (2022), 178 patients with primary membranous nephropathy were identified over two decades. As per the results of this study, remission (partial or complete) was achieved in 134 (75.3%), either spontaneous in 60 (33.7%) or after treatment with immunosuppression in 74 (41.6%), and of these, 57 (42.5%) relapsed. Progression to renal replacement therapy was seen in 10.1%, with mortality in 29.8%.
In 2023, the prevalent population of Idiopathic Membranous Nephropathy in the United States was found to be around 29,000, which will increase to 31,227 cases by 2034.
Among EU4 and the UK, PLA2R and THSD7A antigens were detected in nearly 18,000 and 1,000 IMN patients, respectively.
Key Membranous Nephropathy Companies are as follows: Argenx, Zai Lab Pty Ltd., Shanghai Jiaolian Drug Research and Development Co. Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, Acelyrin, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Gilead Sciences, Mallinckrodt, Mayo Clinic, Genentech Inc., GlaxoSmithKline, Roche Pharma AG, Apellis Pharmaceuticals Inc., and others.
Key Membranous Nephropathy Therapies are as follow: placebo, VB119, Rituximab, MIL62, Cyclosporine, B007, Cyclosporin Capsules, Rituximab, SNP-ACTH (1-39) Gel, Zanubrutinib, Tacrolimus, SHR1459, Placebo, Obinutuzumab, Tacrolimus, Methylprednisolone, Filgotinib, Lanraplenib, belimumab, povetacicept, WAL0921
Launching multiple stage Membranous Nephropathy pipeline products is expected to revolutionize market dynamics, further propelling market growth.

To Know in detail about the Membranous Nephropathy Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Membranous Nephropathy Market Overview:
The Membranous Nephropathy Drugs Market report provides current treatment practices, emerging drugs, Membranous Nephropathy market share of the individual therapies, current and forecasted Membranous Nephropathy market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Membranous Nephropathy treatment market practice/algorithm, Membranous Nephropathy market drivers and market barriers and Membranous Nephropathy unmet needs to curate best of the opportunities and assesses the underlying potential of the Membranous Nephropathy drugs market.

Membranous Nephropathy Drugs Uptake and Pipeline Development Activities:
The drugs uptake section highlights the adoption rate of newly launched or anticipated drugs during the study period. The report includes information on market uptake by drugs, patient uptake by therapies, and sales for each drug. Additionally, it offers insights into the Fabry Disease pipeline, examining therapeutic candidates at various stages and the key companies engaged in their development.

For more information about Membranous Nephropathy companies working in the treatment market, visit https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Membranous Nephropathy Therapies and Key Companies:
Placebo: argenx
VB119: Tenet Medicines
Rituximab: Mayo Clinic
MIL62, Cyclosporine: Beijing Mabworks Biotech Co., Ltd.
B007, Cyclosporin Capsules: Shanghai Jiaolian Drug Research and Development Co., Ltd
Rituximab, SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals, Inc.
Zanubrutinib, Tacrolimus: BeiGene
SHR1459, Placebo: Reistone Biopharma Company Limited
Obinutuzumab, Tacrolimus, Methylprednisolone: Hoffmann-La Roche
Filgotinib, Lanraplenib: Gilead Sciences
Belimumab: GlaxoSmithKline
Povetacicept: Alpine Immune Sciences, Inc.
WAL0921: Walden Biosciences

Membranous Nephropathy Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Membranous Nephropathy.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Membranous Nephropathy Epidemiology Segmentation:
The Membranous Nephropathy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Total Prevalence of Membranous Nephropathy
Prevalent Cases of Membranous Nephropathy by severity
Gender-specific Prevalence of Membranous Nephropathy
Diagnosed Cases of Episodic and Chronic Membranous Nephropathy

Membranous Nephropathy Market Drivers and Barriers:
The Membranous Nephropathy Market Forecast report highlights key drivers and barriers shaping the Membranous Nephropathy market dynamics, providing insights into factors influencing growth and challenges that may be encountered.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Membranous Nephropathy Market Report:
Study Period: 2019-2032
Coverage: 7MM (The United States, EU5, and Japan)
Key Membranous Nephropathy Companies: Argenx, Zai Lab Pty Ltd., Shanghai Jiaolian Drug Research and Development Co. Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, Acelyrin, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Gilead Sciences, Mallinckrodt, Mayo Clinic, Genentech Inc., GlaxoSmithKline, Roche Pharma AG, Apellis Pharmaceuticals Inc., and others.
Key Membranous Nephropathy Therapies: placebo, VB119, Rituximab, MIL62, Cyclosporine, B007, Cyclosporin Capsules, Rituximab, SNP-ACTH (1-39) Gel, Zanubrutinib, Tacrolimus, SHR1459, Placebo, Obinutuzumab, Tacrolimus, Methylprednisolone, Filgotinib, Lanraplenib, belimumab, povetacicept, WAL0921
Membranous Nephropathy Therapeutic Assessment: Current marketed and emerging therapies
Membranous Nephropathy Market Dynamics: Membranous Nephropathy Market drivers and Membranous Nephropathy barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Membranous Nephropathy Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Membranous Nephropathy market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Membranous Nephropathy Executive Summary
3. Competitive Intelligence Analysis for Membranous Nephropathy
4. Membranous Nephropathy: Market Overview at a Glance
5. Membranous Nephropathy: Disease Background and Overview
6. Patient Journey
7. Membranous Nephropathy Epidemiology and Patient Population
8. Membranous Nephropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Membranous Nephropathy Unmet Needs
10. Key Endpoints of Membranous Nephropathy Treatment
11. Membranous Nephropathy Marketed Products
12. Membranous Nephropathy Emerging Therapies
List to be continued in report
13. Membranous Nephropathy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Membranous Nephropathy Market Outlook
16. Membranous Nephropathy Market Access and Reimbursement Overview
17. Membranous Nephropathy KOL Views
18. Membranous Nephropathy Market Drivers
19. Membranous Nephropathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.